Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
International Journal of Cancer|December 20, 2018
Relationship of DNA methylation to mutational changes and transcriptional organization in fusion-positive and fusion-negative rhabdomyosarcomaWenyue Sun, Bishwanath Chatterjee, Jack F Shern, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 26, 2007
Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neckShaoyu Zhou, Sushant Kachhap, Wenyue Sun, et al.
Plos One|March 24, 2009
Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancerIan M Smith, Chad A Glazer, Suhail K Mithani, et al.
Nature Communications|September 16, 2020
Phenotypic profiling with a living biobank of primary rhabdomyosarcoma unravels disease heterogeneity and AKT sensitivityGabriele Manzella, Leonie D Schreck, Willemijn B Breunis, et al.
Plos One|March 27, 2014
Novel insight into mutational landscape of head and neck squamous cell carcinomaDaria A Gaykalova, Elizabeth Mambo, Ashish Choudhary, et al.
Plos One|May 14, 2020
Correction: Novel Insight into Mutational Landscape of Head and Neck Squamous Cell CarcinomaDaria A Gaykalova, Elizabeth Mambo, Ashish Choudhary, et al.
Cancer Research|December 20, 2013
Activation of the NOTCH pathway in head and neck cancerWenyue Sun, Daria A Gaykalova, Michael F Ochs, et al.
Molecular Cancer Therapeutics|April 22, 2026
NAPRT expression and epigenetic regulation in pediatric rhabdomyosarcoma as a potential biomarker for NAMPT inhibitionAngela Kim, Prateek Bhardwaj, Shahyan Rehman, et al.
Biorxiv : the Preprint Server for Biology|August 6, 2025
NAPRT expression and epigenetic regulation in pediatric rhabdomyosarcoma as a potential biomarker for NAMPT inhibitionAngela Kim, Prateek Bhardwaj, Collin D Heer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 2, 2022
The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma ModelsKatie E Hebron, Xiaolin Wan, Jacob S Roth, et al.
Pageof 8